Drugs / Infliximab-CT-P13
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05072782 | Dec 2021 → Jun 2023 | Crohn disease | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Infliximab-CT-P13 | “Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.” NCT05072782 ↗ |
| Route | Intravenous | “two intravenous infusions” NCT05072782 ↗ |